Objective To evaluate the efficacy and side effects of combination therapy with aprepitant,
tropisetron and dexamethasone in the prevention of nausea and vomiting induced by AC …

Purpose: To investigate the clinical efficacy of aprepitant in the prevention of chemotherapy-
induced nausea and vomiting (CINV) caused by schemotherapy after gastric cancer surgery …

Objectives This is a single center, randomized, double-blind placebo-controlled study to
evaluate the NK (1)-receptor antagonist, aprepitant, in Chinese breast cancer patients. The …

Background: The aim of this study was to evaluate whether aprepitant is an effective
antiemetic when combined with 5-hydroxytryptamine 3-(5-HT3) receptor antagonists and …

We retrospectively analyzed the efficacy and safety of aprepitant in breast cancer patients
who were treated with FEC (5-fluorouracil, epirubicin, cyclophosphamide) or EC (epirubicin …

Chemotherapy induced nausea and vomiting (CINV) is one of the few mostly observed
distressing toxicity of cancer treatment. Aprepitant (neurokinin-1 (NK1) receptor antagonist) …

Chemotherapy is a major therapeutic approach for malignant neoplasms; however, due to
the mostcommon adverse events of nausea and vomiting, scheduled chemotherapeutic …

BACKGROUND: Nausea is the first and vomiting the third most distressing side-effect of
cancer chemotherapy. With the introduction of neurokinin-1 receptor antagonist aprepitant …

e21670 Background: Olanzapine has been shown to be a safe and effective agent for the
prevention of CINV. This study aims to compare olanzapine with aprepitant in the prevention …

This study aimed to assess the clinical efficacy and safety of aprepitant injection in
preventing and treating nausea and vomiting induced by platinum‐based chemotherapy in …